Agentix (AGTX) Change in Accured Expenses (2013 - 2024)
Agentix's (AGTX) quarterly Change in Accured Expenses came in at $39118.0 in Q4 2024, up 116.22% YoY from $18092.1 in Q1 2024, and up 116.22% on a QoQ basis from -$241238.0 in Q4 2023.
Agentix (AGTX) Change in Accured Expenses (2013 - 2024) Analysis & Trends
Agentix (AGTX) has 10 years of Change in Accured Expenses data on file, last reported at $39118.0 in Q4 2024.
- Quarterly Change in Accured Expenses rose 116.22% year-over-year to $39118.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$193618.0 (up 15.28% YoY) and the FY2019 annual result came in at $61772.0, down 25.11% from the prior year.
- Change in Accured Expenses rose to $39118.0 in Q4 2024, from -$241238.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $39118.0 in Q4 2024 to a low of -$241238.0 in Q4 2023.
- A 3-year average of -$64539.3 and a median of $8502.0 in 2020 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2020 — Change in Accured Expenses tumbled 57.49% — and 2024, when it jumped 116.22%.
- Tracing AGTX's Change in Accured Expenses over 3 years: stood at $8502.0 in 2020, then plunged by 2937.43% to -$241238.0 in 2023, then jumped by 116.22% to $39118.0 in 2024.
- The last three Change in Accured Expenses figures came in at $39118.0 (Q4 2024), -$241238.0 (Q4 2023), and $8502.0 (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 39,118.00 |
| Dec 31, 2024 | 39,118.00 |
| Dec 31, 2023 | -241,238.00 |
| Dec 31, 2023 | -241,238.00 |
| May 31, 2020 | 8,502.00 |
| May 31, 2020 | 8,502.00 |
| Nov 30, 2019 | 4,195.00 |
| Nov 30, 2019 | 4,195.00 |
| Aug 31, 2019 | 3,181.00 |
| Aug 31, 2019 | 3,181.00 |
| May 31, 2019 | 20,000.00 |
| May 31, 2019 | 20,000.00 |
| Feb 28, 2019 | 37,743.00 |
| Feb 28, 2019 | 37,743.00 |
| Nov 30, 2018 | 848.00 |
| Nov 30, 2018 | 848.00 |
| Aug 31, 2018 | 21,408.00 |
| Aug 31, 2018 | 21,408.00 |
| May 31, 2018 | 20,723.00 |
| May 31, 2018 | 20,723.00 |